{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:37:25Z","timestamp":1793050645291,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01-CA129243"],"award-info":[{"award-number":["P01-CA129243"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017042","name":"Fiona and Stanley Druckenmiller Center for Lung Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R35 CA210085"],"award-info":[{"award-number":["R35 CA210085"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012231","name":"Society of Memorial Sloan Kettering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012231","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.celrep.2026.117559","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:09:10Z","timestamp":1781827750000},"page":"117559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Distinct ERK and PI3K dependencies mediate a heterogeneous response to RAS(ON) inhibition in KRAS-mutant colorectal cancer"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8185-4563","authenticated-orcid":false,"given":"Philip H.","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Meredith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malvika","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Markov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"de Stanchina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallika","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2026.117559_bib1","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3390\/cancers16081530","article-title":"Colorectal Cancer: Epidemiology, Risk Factors, and Prevention","volume":"16","author":"Roshandel","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.celrep.2026.117559_bib2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12943-021-01441-4","article-title":"Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer","volume":"20","author":"Zhu","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.celrep.2026.117559_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.celrep.2026.117559_bib4","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","article-title":"Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer","volume":"14","author":"Yaeger","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2026.117559_bib5","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.celrep.2026.117559_bib6","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/2159-8290.CD-25-0349","article-title":"Response and Resistance to RAS Inhibition in Cancer","volume":"15","author":"Ebright","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2026.117559_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1158\/2159-8290.CD-22-0405","article-title":"Molecular characterization of acquired resistance to KRAS G12C-EGFR inhibition in colorectal cancer","volume":"13","author":"Yaeger","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2026.117559_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110993","article-title":"KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy","volume":"39","author":"Ryan","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2026.117559_bib9","article-title":"Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization","volume":"9","author":"Maruyama","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.celrep.2026.117559_bib10","doi-asserted-by":"crossref","first-page":"6804","DOI":"10.1158\/0008-5472.CAN-10-0409","article-title":"PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK\/ERK and mutant KRAS signaling","volume":"70","author":"Halilovic","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117559_bib11","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1172\/JCI57909","article-title":"Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers","volume":"121","author":"Ebi","year":"2011","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.celrep.2026.117559_bib12","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186035","article-title":"LIN28B-mediated PI3K\/AKT pathway activation promotes metastasis in colorectal cancer models","volume":"135","author":"Shin","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.celrep.2026.117559_bib13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ccell.2017.12.004","article-title":"Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer","volume":"33","author":"Yaeger","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2026.117559_bib14","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2026.117559_bib15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s11523-022-00898-7","article-title":"Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer","volume":"17","author":"Tan","year":"2022","journal-title":"Target. Oncol."},{"key":"10.1016\/j.celrep.2026.117559_bib16","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41419-018-0776-6","article-title":"PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer","volume":"9","author":"Wang","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.celrep.2026.117559_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz246.108","article-title":"PIK3CA mutation in metastatic colorectal cancer (mCRC): Association with clinico-pathological features and outcome","volume":"30","author":"Fanotto","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.celrep.2026.117559_bib18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12964-023-01225-x","article-title":"PI3K\/AKT signaling pathway as a critical regulator of epithelial-mesenchymal transition in colorectal tumor cells","volume":"21","author":"Maharati","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.celrep.2026.117559_bib19","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1038\/bjc.2014.100","article-title":"Activation of the PI3K\/AKT pathway correlates with prognosis in stage II colon cancer","volume":"110","author":"Malinowsky","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.celrep.2026.117559_bib20","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","article-title":"Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy","volume":"629","author":"Holderfield","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.117559_bib21","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.1038\/s41467-024-50063-z","article-title":"Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer","volume":"15","author":"Kitai","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.117559_bib22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ccr.2010.05.023","article-title":"4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors","volume":"18","author":"She","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2026.117559_bib23","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","article-title":"The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation","volume":"36","author":"Mendoza","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.celrep.2026.117559_bib24","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.celrep.2026.117559_bib25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1947601911408079","article-title":"Ras interaction with PI3K: More than just another effector pathway","volume":"2","author":"Castellano","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.celrep.2026.117559_bib26","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/0008-5472.CAN-08-4765","article-title":"PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers","volume":"69","author":"Wee","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117559_bib27","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1158\/1078-0432.CCR-18-0368","article-title":"KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition","volume":"25","author":"Misale","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117559_bib28","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.1890","article-title":"Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers","volume":"14","author":"Engelman","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2026.117559_bib29","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1073\/pnas.0900780106","article-title":"V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway","volume":"106","author":"Pratilas","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2026.117559_bib30","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","article-title":"Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2026.117559_bib31","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","article-title":"Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer","volume":"629","author":"Wasko","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.117559_bib32","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3390\/jcm12020572","article-title":"Prognostic Potential of Cyclin D1 Expression in Colorectal Cancer","volume":"12","author":"Jun","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.celrep.2026.117559_bib33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41392-024-01907-z","article-title":"MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer","volume":"9","author":"Casacuberta-Serra","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.celrep.2026.117559_bib34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41698-018-0049-y","article-title":"Interaction between Wnt\/\u03b2-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of \u03b2-catenin and RAS by targeting the Wnt\/\u03b2-catenin pathway","volume":"2","author":"Jeong","year":"2018","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.celrep.2026.117559_bib35","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1021\/acs.jmedchem.2c01658","article-title":"Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors","volume":"66","author":"Burnett","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.celrep.2026.117559_bib36","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/s41589-021-00813-7","article-title":"Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth","volume":"17","author":"Lee","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.celrep.2026.117559_bib37","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2424286122","article-title":"eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer","volume":"122","author":"Boyer","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2026.117559_bib38","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/oncolo\/oyac222","article-title":"Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS\/NRAS\/BRAF Wild-Type Colorectal Cancer","volume":"27","author":"Sorah","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.celrep.2026.117559_bib39","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1158\/0008-5472.CAN-22-0198","article-title":"Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4\/6","volume":"82","author":"Sorokin","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117559_bib40","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","article-title":"Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer","volume":"76","author":"Herrera-Abreu","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117559_bib41","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.adg9652","article-title":"Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS","volume":"381","author":"Schulze","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.celrep.2026.117559_bib42","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1158\/0008-5472.CAN-18-0430","article-title":"HER2 amplification in tumors activates PI3K\/Akt signaling independent of HER3","volume":"78","author":"Ruiz-Saenz","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117559_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/science.adk0775","article-title":"Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers","volume":"384","author":"Klomp","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.celrep.2026.117559_bib44","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1158\/2159-8290.CD-23-0866","article-title":"Epigenetic and oncogenic inhibitors cooperatively drive differentiation and kill KRAS-mutant colorectal cancers","volume":"14","author":"Loi","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2026.117559_bib45","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41416-019-0434-5","article-title":"Targeting \u03b2-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations","volume":"120","author":"Moon","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.celrep.2026.117559_bib46","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/18884","article-title":"Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells","volume":"398","author":"Tetsu","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.117559_bib47","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/2159-8290.CD-25-0679","article-title":"A plastic EMP1+ to LGR5+ cell state conversion as a bypass to KRAS-G12D pharmacological inhibition in metastatic colorectal cancer","volume":"16","author":"Centonze","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2026.117559_bib48","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41467-023-44342-4","article-title":"KRAS allelic imbalance drives tumour initiation yet suppresses metastasis in colorectal cancer in vivo","volume":"15","author":"Najumudeen","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.117559_bib49","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.cellsig.2007.10.018","article-title":"GSK-3\u03b2 regulates cyclin D1 expression: A new target for chemotherapy","volume":"20","author":"Takahashi-Yanaga","year":"2008","journal-title":"Cell. Signal."},{"key":"10.1016\/j.celrep.2026.117559_bib50","doi-asserted-by":"crossref","first-page":"7842","DOI":"10.1128\/MCB.22.22.7842-7852.2002","article-title":"Cell Cycle Inhibition by FoxO Forkhead Transcription Factors Involves Downregulation of Cyclin D","volume":"22","author":"Schmidt","year":"2002","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.celrep.2026.117559_bib51","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/2159-8290.CD-13-0611","article-title":"Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling","volume":"4","author":"Will","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2026.117559_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.757120","article-title":"Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment","volume":"12","author":"Thoma","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.celrep.2026.117559_bib53","doi-asserted-by":"crossref","first-page":"pe16","DOI":"10.1126\/scisignal.2001948","article-title":"Resistance to MEK inhibitors: Should we co-target upstream?","volume":"4","author":"Poulikakos","year":"2011","journal-title":"Sci. Signal."},{"key":"10.1016\/j.celrep.2026.117559_bib54","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1158\/2159-8290.CD-18-1175","article-title":"Challenges for the clinical development of PI3K inhibitors: Strategies to improve their impact in solid tumors","volume":"9","author":"Hanker","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2026.117559_bib55","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.adq2004","article-title":"BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3K\u03b1 interaction","volume":"389","author":"Simanshu","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.celrep.2026.117559_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/science.ads0239","article-title":"A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors","volume":"389","author":"Weller","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.celrep.2026.117559_bib57","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1158\/2159-8290.CD-23-0396","article-title":"STX-478, a Mutant-Selective, Allosteric PI3K\u03b1 Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3K\u03b1-Mutant Xenografts","volume":"13","author":"Buckbinder","year":"2023","journal-title":"Cancer Discov."}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124726006376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124726006376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:18:01Z","timestamp":1793049481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124726006376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2211124726006376"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2026.117559","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct ERK and PI3K dependencies mediate a heterogeneous response to RAS(ON) inhibition in KRAS-mutant colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2026.117559","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117559"}}